Taher A, Vichinsky E, Musallam K, Cappellini M-D, Viprakasit V.

Androulla Eleftheriou

Androulla Eleftheriou

قد تم الانتهاء من دراسة تجريبية بمركز نيقوسيا لرعاية مرضى الثلاسيميا، عن طريق رفع المعلومات المعنية بعدد 390 مريض مصاب بالثاليسميا بيتاβالحادة.تم عرض نتائج تحليل البيانات في ورشة عمل عقدت في 20 أكتوبر 2011 بقبرص. وقد سمح هذا المشروع للاتحاد بالتحقق من قيمة هذه البرمجيات كونها وسيلة لتوفير خدمة للمرضى ...

An orphan medicinal product is one that is intended for the diagnosis, prevention or treatment of a condition that affects not more than 5 in 10 000 persons, according to the Regulation (EC) No 141/2000 on Orphan Medicinal Products which promotes research and development of medicines to treat rare diseases.

Rare diseases, including those of genetic origin, are life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them. As a guide, low prevalence is taken as prevalence of less than 5 per 10,000 in the Community.

On 19 January 2011, the European Parliament voted in favour of the EU Directive on cross-border healthcare, a move hailed on that same day by European Commissioner for Health and Consumer Policy, John Dalli, as an important step forward for all patients in European countries.

A clinical trial in the European Union is defined by Directive 2001/20/EC, as a clinical study that aims to investigate the therapeutic effect(s) of medicinal products that have not yet been authorized by regulatory bodies such as the European Medicines Agency (EMA), or the value of authorized drugs in cases ...

It is a well known fact that little is truly known about any medicinal product prior to its entry into the market and interaction with a more diverse population than that of clinical trial participants. Therefore, drugs continue to be monitored once they are put on the market so as ...